AU2001251011A1 - Treatments for immune-mediated ear disorders - Google Patents

Treatments for immune-mediated ear disorders

Info

Publication number
AU2001251011A1
AU2001251011A1 AU2001251011A AU5101101A AU2001251011A1 AU 2001251011 A1 AU2001251011 A1 AU 2001251011A1 AU 2001251011 A AU2001251011 A AU 2001251011A AU 5101101 A AU5101101 A AU 5101101A AU 2001251011 A1 AU2001251011 A1 AU 2001251011A1
Authority
AU
Australia
Prior art keywords
immune
treatments
ear disorders
mediated ear
mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001251011A
Other languages
English (en)
Inventor
Hyon K. Choi
Dennis S. Poe
Mahboob U. Rahman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU2001251011A1 publication Critical patent/AU2001251011A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001251011A 2000-03-27 2001-03-27 Treatments for immune-mediated ear disorders Abandoned AU2001251011A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19229900P 2000-03-27 2000-03-27
US60192299 2000-03-27
PCT/US2001/009725 WO2001072298A1 (fr) 2000-03-27 2001-03-27 Traitement pour troubles des oreilles a mediation immunitaire

Publications (1)

Publication Number Publication Date
AU2001251011A1 true AU2001251011A1 (en) 2001-10-08

Family

ID=22709102

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001251011A Abandoned AU2001251011A1 (en) 2000-03-27 2001-03-27 Treatments for immune-mediated ear disorders

Country Status (3)

Country Link
US (2) US6548527B2 (fr)
AU (1) AU2001251011A1 (fr)
WO (1) WO2001072298A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US8119127B2 (en) * 1999-02-24 2012-02-21 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
AU2001251011A1 (en) * 2000-03-27 2001-10-08 The General Hospital Corporation Treatments for immune-mediated ear disorders
US20030157061A1 (en) * 2001-12-05 2003-08-21 Pharmacia Corporation Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
PT1608407E (pt) * 2003-03-20 2006-12-29 Pharmacia Corp Formulação dispersível de um agente anti-inflamatório
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
WO2005023187A2 (fr) * 2003-08-28 2005-03-17 Kem David C Inhibiteur de tachyarythmies cardiaques
EP1763346A4 (fr) * 2004-05-21 2009-03-04 Uab Research Foundation Composition et methodes se rapportant aux inhibiteurs de la synthese de la pyrimidine
FR2882557A1 (fr) * 2005-02-25 2006-09-01 Centre Nat Rech Scient Epitopes de vih et composition pharmaceutique les contenant
US9132087B2 (en) 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
UY31779A (es) * 2008-04-21 2009-12-14 Univ California Formulaciones para el oído para tratar enfermedades y condiciones opticas
KR101534422B1 (ko) 2008-05-14 2015-07-09 오토노미, 인코포레이티드 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
US8648119B2 (en) * 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
EP3786164A1 (fr) * 2015-06-18 2021-03-03 Ting Therapeutics LLC Procédés et compositions pour la prévention et le traitement de la perte auditive
US20180021315A1 (en) * 2016-07-20 2018-01-25 Wayne State University Methods of treating hearing disorders
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905090A (en) * 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
AU2001251011A1 (en) * 2000-03-27 2001-10-08 The General Hospital Corporation Treatments for immune-mediated ear disorders
JP3672803B2 (ja) * 2000-07-28 2005-07-20 Ｎｅｃエレクトロニクス株式会社 不揮発性記憶装置

Also Published As

Publication number Publication date
US6548527B2 (en) 2003-04-15
WO2001072298A1 (fr) 2001-10-04
US20020044920A1 (en) 2002-04-18
US20040072885A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
AU2001251011A1 (en) Treatments for immune-mediated ear disorders
AU2002223827A1 (en) Well treatment
AU2001227916A1 (en) Earplug
AU2001252135A1 (en) Therapeutic agents
AU2002222659A1 (en) Film-reinforced glasses
AU2001271561A1 (en) Network kiosk
AU2042301A (en) 1-aminoalkyl-1H-indoles for treating glaucoma
AU2002313816A1 (en) Ear coupler
AU2002335743A1 (en) Audio distributor
AU2001237939A1 (en) Methods for treating glaucoma
AU5256301A (en) Froindazole derivative
AU2001265871A1 (en) Substituted sulfonylaminopyrimidines
AU2001254731A1 (en) Substituted phenyluracils
AU2001258255A1 (en) Substituted benzoylcyclohexenones
AU2001220281A1 (en) Rollerboard for road-skiing
AU2001237546A1 (en) Methods for characterizing polymorphisms
AU2001273903A1 (en) Therapeutic agents
AU2001266204A1 (en) Eyewear
AU5822601A (en) Headstock
AU2001245781A1 (en) Cd18-binding antibodies inhibit stenosis-related disorders
AU2002223604A1 (en) Substituted phenyluracils
AU2001228493A1 (en) Adjusting device
AU2001250569A1 (en) An account
AU2001292897A1 (en) Novel therapy
AU2001240552A1 (en) Ceramidase